Filing Flows › Exagen (XGN) › Q2 2026
Exagen (XGN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Exagen (XGN) reported revenue of $19.9M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +15% from the quarter before. Operating margin was -8.6%, net loss $3.2M (16.0% of revenue).
Exagen, Q2 2026: revenue $19.9M (+16% year over year), operating margin -8.6%, net loss $3.2M, operating cash flow $4.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.9M | +15% | +16% |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$3.2M | — | — |
| Operating cash flow | $4.0M | — | — |
| Free cash flow | $3.4M | — | — |
What changed
Revenue was $19.9M in Q2 2026, up 16% year over year and up 15% from the previous quarter.
Gross margin was 61.3%, up 0.8 points from Q2 2025. Operating costs exceeded revenue by $1.7M, an operating margin of -8.6%. Operating expenses grew 7% against revenue growth of 16%. The quarter ended with a net loss of $3.2M, narrower than the previous quarter's $4.0M loss.
Operating cash flow was $4.0M. Non-cash charges added back $600K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items added $5.6M. Capital expenditures of $543K left free cash flow of $3.4M.
Questions
What was Exagen's revenue in the second quarter 2026?
Exagen (XGN) reported revenue of $19.9M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +15% from the quarter before.
Was Exagen profitable in the second quarter 2026?
Operating loss was $1.7M (-8.6% of revenue) and net loss $3.2M.
Source: Exagen 10-Q on SEC EDGAR.